Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024)
Acumen Pharmaceuticals (ABOS) reported Operating Leases of $185000.0 for Q3 2024, down 15.53% sequentially from $219000.0 in Q2 2024.
Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 3 years of Operating Leases data on file, last reported at $185000.0 in Q3 2024.
- For the quarter ending Q3 2024, Operating Leases changed N/A year-over-year to $185000.0; the trailing twelve-month figure through Sep 2024 stood at $185000.0 (changed N/A YoY), and the FY2023 full-year result was $284000.0, changed N/A from the prior year.
- Operating Leases eased to $185000.0 in Q3 2024, from $219000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $284000.0 in Q4 2023 to a low of $62000.0 in Q1 2022.
- A 3-year average of $186000.0 and a median of $185000.0 in 2024 frame the typical range for Operating Leases.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 219,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 284,000.00 |
| Sep 30, 2022 | 133,000.00 |
| Jun 30, 2022 | 167,000.00 |
| Mar 31, 2022 | 62,000.00 |